Home
Stig Wergeland's picture

Stig Wergeland

Associate Professor
  • E-mails.wergeland@uib.no
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and neuroinflammation. 1-10.
  • Show author(s) (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry. 849-857.
  • Show author(s) (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
  • Show author(s) (2022). Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 645-650.
  • Show author(s) (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology. 5901-5909.
  • Show author(s) (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-10.
  • Show author(s) (2021). Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-10.
  • Show author(s) (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. Neurology. e2789-e2800.
  • Show author(s) (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Multiple Sclerosis and Related Disorders. 1-7.
  • Show author(s) (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
  • Show author(s) (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. Tidsskrift for Den norske legeforening.
  • Show author(s) (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. Scientific Reports. 16 pages.
  • Show author(s) (2021). A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. PLOS ONE. 1-16.
  • Show author(s) (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology.
  • Show author(s) (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
  • Show author(s) (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology. 73-77.
  • Show author(s) (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. Journal of Neuroimmunology. 61-65.
  • Show author(s) (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
  • Show author(s) (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
  • Show author(s) (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
  • Show author(s) (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
  • Show author(s) (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
  • Show author(s) (2016). No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
  • Show author(s) (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
  • Show author(s) (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • Show author(s) (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • Show author(s) (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. Multiple Sclerosis. 1013-1024.
  • Show author(s) (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.
  • Show author(s) (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
  • Show author(s) (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • Show author(s) (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
  • Show author(s) (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
  • Show author(s) (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
  • Show author(s) (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
  • Show author(s) (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • Show author(s) (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.
  • Show author(s) (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
  • Show author(s) (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
  • Show author(s) (2012). The cuprizone model: regional heterogeneity of pathology. APMIS - Journal of Pathologiy, Microbiology and Immunology. 648-657.
  • Show author(s) (2012). A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
  • Show author(s) (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 pages.
Academic lecture
  • Show author(s) (2015). Vitamin D og interferon-behandling ved multippel sklerose.
Short communication
  • Show author(s) (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. Neurology: Neuroimmunology and neuroinflammation.
Feature article
  • Show author(s) (2022). Amming og behandling av multippel sklerose. Tidsskrift for Den norske legeforening. 1-5.
Letter to the editor
  • Show author(s) (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders.
  • Show author(s) (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. European Journal of Neurology. e104-e104.
Doctoral dissertation
  • Show author(s) (2013). Vitamin D and ω-3 polyunsaturated fatty acids as disease modifying factors in multiple sclerosis.
Abstract
  • Show author(s) (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
  • Show author(s) (2013). Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. Multiple Sclerosis. 33-34.
  • Show author(s) (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
  • Show author(s) (2009). Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
Poster
  • Show author(s) (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis.
  • Show author(s) (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis.
  • Show author(s) (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies.
  • Show author(s) (2014). Magnetization transfer ratio (MTR) increased unexpectedly in EAE induced mice.
Academic literature review
  • Show author(s) (2015). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
  • Show author(s) (2013). Neuromyelitis optica. Tidsskrift for Den norske legeforening. 2057-2061.
  • Show author(s) (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.

More information in national current research information system (CRIStin)